Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Zoetis (ZTS) today and set a price target of $116. The company’s shares closed on Friday at $100.67, close to its 52-week high of $100.94.
“. We have increased our 1Q19E EPS to $0.77 from $0.49 before. The increase in our 1Q19 EPS estimate is driven by raising our revenue forecasts for 1Q19 and 2019. Our annual 2019 EPS estimate of $3.42 remains unchanged. We are also raising our PT for ZTS shares to $116 from $105. The increase in our PT is based on upward sales revisions and multiple expansion. We think this is deserved since ZTS is performing above our expectations.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.4% and a 46.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Zoetis has an analyst consensus of Moderate Buy, with a price target consensus of $108.
See today’s analyst top recommended stocks >>
The company has a one-year high of $100.94 and a one-year low of $77. Currently, Zoetis has an average volume of 2.41M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. Last month, Catherine Knupp, the EVP of ZTS sold 32,767 shares for a total of $3,139,079.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.